🔹Novo Nordisk has announced a major investment of DKr8.5bn ($1.2bn) to establish a new production facility in Odense, Denmark. The facility, unveiled on December 16, will focus on manufacturing therapies for rare diseases, including treatments for haemophilia.
🔹The site will also feature a warehouse spanning over 40,000m². This development is expected to enhance Novo Nordisk’s capacity for producing innovative treatments and contribute significantly to Denmark’s pharmaceutical industry.
🔹Novo Nordisk’s haemophilia portfolio features Alhemo (concizumab) and the antibody Mim8, with its Phase III FRONTIER2 trial (NCT05053139) for haemophilia A completed earlier this year, although the company has yet to publish the results. Additionally, Novo Nordisk is conducting a Phase I trial (NCT06649630) for its oral antibody Inno8, also targeting haemophilia.
🔹This announcement follows Novo Holdings’ recent $16.5bn acquisition of Catalent, a global contract development and manufacturing organization. Approved by the Federal Trade Commission and the European Commission, the deal is expected to bolster the production of Novo Nordisk’s glucagon-like peptide-1 receptor agonists (GLP-1RAs), Wegovy and Ozempic, which have faced global supply shortages.
🔹Construction of the Odense facility is already underway, with completion anticipated by 2027. The project will engage up to 1,000 external workers during construction and create 400 permanent positions upon completion.
Henrik Wulff, Novo Nordisk’s executive vice president of product supply, quality, and IT, stated:
“The facility will utilise advanced technology and innovative equipment to ensure the highest quality for patients and meet the growing global demand for our life-changing medicines.”